UPFRONT CLOPIDOGREL USE AND THE EFFICACY AND SAFETY OF EARLY EPTIFIBATIDE USE IN PATIENTS WITH ACUTE CORONARY SYNDROME: AN ANALYSIS FROM THE EARLY VERSUS DELAYED PROVISIONAL EPTIFIBATIDE IN ACUTE CORONARY SYNDROMES (EARLY ACS) TRIAL  by Wang, Tracy et al.
A47.E451
JACC March 9, 2010
Volume 55, issue 10A
 HYPERTENSION, LIPIDS AND PREVENTION 
UPFRONT CLOPIDOGREL USE AND THE EFFICACY AND SAFETY OF EARLY EPTIFIBATIDE USE IN 
PATIENTS WITH ACUTE CORONARY SYNDROME: AN ANALYSIS FROM THE EARLY VERSUS DELAYED 
PROVISIONAL EPTIFIBATIDE IN ACUTE CORONARY SYNDROMES (EARLY ACS) TRIAL
ACC Oral Contributions
Georgia World Congress Center, Room B408
Monday, March 15, 2010, 11:15 a.m.-11:30 a.m.
Session Title: Antiplatelet Agents and Coronary Artery Disease
Abstract Category: Pharmacology/Hormones/Lipids—Clinical
Presentation Number: 0908-06
Authors: Tracy Wang, Jennifer A. White, Robert P. Giugliano, Pierluigi Tricoci, Robert A. Harrington, Gilles Montalescot, Uwe Zeymer, Frans Van de Werf, 
Paul W. Armstrong, Eugene Braunwald, Robert M. Califf, L. Kristin Newby, Duke Clinical Research Institute, Durham, NC
Background: In EARLY ACS, routine early eptifibatide before angiography was not superior to delayed provisional use during PCI, but led to more 
bleeding. The efficacy and safety of early eptifibatide with upfront clopidogrel use is unknown.
Methods: EARLY ACS randomized patients to eptifibatide or placebo for >=12 hours before angiography. Clopidogrel use and timing were 
determined by treating physicians. We examined the interaction of upfront (before angiography) clopidogrel with early eptifibatide on efficacy (30-
day death/MI) and safety (in-hospital GUSTO moderate/severe bleeding) end points using multivariable logistic regression modeling.
Results: Of 9166 patients who had coronary angiography, 7074 (77%) received upfront clopidogrel. Geographic heterogeneity in upfront 
clopidogrel use was substantial (North America, 56%, v. other, 87%; p<0.001); otherwise, patient features were similar between groups. After 
adjustment for clinical covariates and region, early eptifibatide significantly reduced death/MI among patients treated with upfront clopidogrel 
(Figure); there was no effect in patients without upfront clopidogrel (interaction p = 0.058). Early eptifibatide increased bleeding regardless of 
upfront clopidogrel use (interaction p = 0.371).
Conclusions: Early eptifibatide and upfront clopidogrel use was associated with lower ischemic risk in ACS 
patients undergoing angiography. Clopidogrel use did not accentuate bleeding associated with early eptifibatide use.
